Telix Pharmaceuticals Limited
NASDAQTotal Valuation
Telix Pharmaceuticals Limited carries a market capitalization of 3.70B, placing it among publicly traded companies globally. Its enterprise value stands at -72.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.70B |
| Enterprise Value | -72.03M |
Share Statistics
Telix Pharmaceuticals Limited currently has 323.73M shares outstanding.
| Shares Outstanding | 323.73M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Telix Pharmaceuticals Limited maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.42 |
| Quick Ratio | 1.20 |
| Debt / Equity | 11.95 |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Stock Price Statistics
Telix Pharmaceuticals Limited's stock has declined approximately -33.81818% over the past 52 weeks. The 50-day moving average sits at 10.37, while the 200-day moving average is 9.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.81818% |
| 50-Day Moving Average | 10.37 |
| 200-Day Moving Average | 9.30 |
| Average Volume (20 Days) | N/A |
Balance Sheet
Telix Pharmaceuticals Limited holds 84.30M in cash and equivalents against 12.26M in total debt, resulting in a net debt position of -77.69M. Total book value stands at -187.12M, with working capital of 47.32M providing operational flexibility.
| Cash & Cash Equivalents | 84.30M |
| Total Debt | 12.26M |
| Net Debt | -77.69M |
| Equity (Book Value) | -187.12M |
| Book Value Per Share | N/A |
| Working Capital | 47.32M |
Scores
Telix Pharmaceuticals Limited posts an Altman Z-Score of -1.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.01 |